Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Ewing sarcoma (EWS) has a poor prognosis in refractory/relapsed cases, necessitating novel treatments.
• Cellular immunotherapies show promise for advanced EWS but depend on human leukocyte antigen (HLA) expression for immune recognition.
• Understanding HLA expression in EWS is crucial for developing effective immunotherapeutic strategies.

Purpose of the Study:

• To analyze human leukocyte antigen (HLA) class I and class II expression in Ewing sarcoma (EWS) cell lines and tumors.
• To investigate the mechanisms regulating HLA expression and its potential role in immune evasion in EWS.
• To provide foundational knowledge for designing cellular immunotherapies for advanced-stage EWS.

Main Methods:

• Flow cytometry and immunofluorescence were used to assess HLA class I and II expression in EWS cell lines and patient tumors.
• Western blot and qRT-PCR were employed to evaluate the expression of key components of the antigen processing and presentation machinery.
• Functional assays were conducted to assess the inducibility of HLA expression by interferon-gamma (IFNγ) and the role of CIITA.

Main Results:

• A significant proportion (79%) of EWS tumors exhibited complete or partial absence of HLA class I expression, with lung metastases consistently lacking expression.
• EWS cells demonstrated a lack of functional CIITA, resulting in absent IFNγ-inducible HLA class II expression.
• Heterogeneity in constitutive HLA class I expression appears regulated by mechanisms involving IFNγ-inducible components of the antigen processing pathway.

Conclusions:

• The majority of EWS tumors, especially advanced-stage ones, display a significant deficiency in both HLA class I and II expression.
• This widespread absence of HLA expression suggests a potential immune escape mechanism in EWS.
• The findings underscore the importance of characterizing HLA expression profiles for the rational design of cellular immunotherapies targeting EWS.